Lipoxygenase inhibitors

Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

560 1, 560100, 560 53, 560105, 560106, 560163, 560312, 562463, 562621, 568425, 568659, 568662, 568807, C07C 6702

Patent

active

055632920

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

This invention relates to certain phenyl-alkylphenyl compounds which are useful as inhibitors of the lipoxygenase pathways in the metabolism of arachidonic acid.


BACKGROUND OF THE INVENTION

A number of lipoxygenase inhibitors are known. For example, International Application Number PCT/US86/02548, International Publication Number WO 88/03800 published Jun. 2, 1988 discloses compounds having the formula: ##STR2## wherein D, E, F, X, Y, Z, may be H; OH; O-alkyl; or O-acyl optionally substituted with hydroxy, alkoxy, substituted amino, carboxyl, or carbalkoxyl; R.sub.1 to R.sub.6 may be H; lower alkyl or lower alkoxyl optionally substituted with hydroxy, alkoxy, substituted amino, carboxyl, or carbalkoxyl; carbonyl; alkoxy; aryl; or aralkyl; and n may be 0 to 5.
Arachidonic acid is metabolized by means of the enzymes 5-lipoxygenase and cyclooxygenase into various leukotrienes, including slow reacting substances, and prostaglandins which cause allergic reactions, inflammation and hyperproliferative skin diseases. Inhibition of the activity of 5-lipoxygenase (5-LO) reduces the manifestation of the symptoms of allergic reactions, e.g. chronic obstructive lung disease such as asthma, allergic or seasonal rhinitis, bronchitis, and the like; inflammatory diseases such as arthritis, bursitis, tendonitis, gout and inflammatory bowel disease; hypoproliferative skin disease, a symptom of which is accelerated skin cell production manifested by flaking, scales or papular lesions, e.g., psoriasis, lichenified eczema, dandruff, and the like.
A welcome contribution to the art would be novel organic compounds which are useful as lipoxygenase inhibitors. Such a contribution is provided by this invention.


SUMMARY OF THE INVENTION

This invention provides compounds having particularly advantageous properties useful in the treatment of inflammatory and allergic reactions by inhibiting the formation of 5-lipoxygenase derived products of arachidonic acid metabolism. One embodiment of this invention provides compounds represented by Formula 1: ##STR3## or a pharmaceutically acceptable salt or solvate thereof wherein:
(A) R.sup.1 and R.sup.2 are the same or different and are selected from: substituted aryl, heteroaryl, --OR.sup.5, and --NR.sup.6 R.sup.7 ; independently substituted by substituents selected from alkyl and --O-alkyl; and
(B) R.sup.3 and R.sup.4 are the same or different and are independently selected from H, R.sup.1 and R.sup.2 ;
(C) U, V, and Z are the same or different and are independently selected from H, R.sup.1, R.sup.2, --OR.sup.10, --O(CH.sub.2).sub.m R.sup.8, --OC(O)R.sup.9, and --OC(O)NR.sup.6 R.sup.7 ; and
(D) W is --(CH.sub.2).sub.n X wherein X is selected from:
n is an integer from 1 to 8;
wherein
R.sup.5 is selected from H, alkyl, aryl, alkaryl, aralkyl, cycloalkyl, and heteroaryl with the proviso that said heteroaryl group is bound through a ring carbon;
R.sup.6 and R.sup.7 are the same or different and are independently selected from H, alkyl, aryl, aralkyl, acyl substituted aryl, cycloalkyl and heteroaryl, with the proviso that when R.sup.6 and/or R.sup.7 is a heteroaryl group said heteroaryl group is bound by a ring carbon;
R.sup.8 is selected from aryl, substituted aryl, and heteroaryl, with the proviso that said heteroaryl group is bound through a ring carbon;
R.sup.9 is selected from H, alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, and heteroaryl, with the proviso that said heteroaryl group is bound through a ring carbon;
m is an integer from 1 to 4;
R.sup.10 is selected from H and alkyl; and.
R.sup.11 is selected from H, --OR.sup.5, --NR.sup.6 R.sup.7, and --NR.sup.5 OH.
Preferred compounds of this invention are represented by Formula 2: ##STR4## wherein R.sup.12 and R.sup.13 are the same or different and are independently selected from U, V, and Z as defined for Formula 1 and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and W are as defined for Formula 1.
More preferred compounds of this invention are represented by Formula 3: ##STR5## wherein R.sup.14 and R.sup.15 are th

REFERENCES:
patent: 4584320 (1985-04-01), Rubin
patent: 4708964 (1987-11-01), Allen
Asahara et al Bull. Jap. Petrol Insl. 12 49-53 1970.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Lipoxygenase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipoxygenase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoxygenase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-58590

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.